<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sebelipase alfa: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sebelipase alfa: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sebelipase alfa: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="106038" href="/d/html/106038.html" rel="external">see "Sebelipase alfa: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="108897" href="/d/html/108897.html" rel="external">see "Sebelipase alfa: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45820938"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kanuma</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872118"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Kanuma</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F45759567"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Enzyme</li></ul></div>
<div class="block doa drugH1Div" id="F46127920"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b42c0bec-9b1d-46bf-9943-5f726b01efe1">Lysosomal acid lipase deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Lysosomal acid lipase deficiency:</b>
<b>IV:</b> 1 mg/kg every other week; may increase to 3 mg/kg every other week in patients with suboptimal response (poor growth, deteriorating biochemical markers [eg, ALT, AST], and/or parameters of lipid metabolism [eg, low-density lipoprotein cholesterol, triglycerides]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991971"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989329"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F46127924"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate hypersensitivity reaction: Interrupt infusion; consider resuming at slower infusion rate.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hypersensitivity reaction or anaphylaxis: Immediately discontinue infusion.</p></div>
<div class="block doe drugH1Div" id="F46127921"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b></b>Refer to adult dosing; has not been studied.</p></div>
<div class="block dop drugH1Div" id="F46127919"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="108897" href="/d/html/108897.html" rel="external">see "Sebelipase alfa: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f132957-ccad-4b20-835b-6fcf8e769bd0">Lysosomal acid lipase deficiency; rapidly progressive presenting within the first 6 months of life</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lysosomal acid lipase (LAL) deficiency; rapidly progressive presenting within the first 6 months of life:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Initial: 1 mg/kg/dose once weekly; may increase to 3 mg/kg/dose once weekly if response not optimal; if response remains not optimal may further increase to 5 mg/kg/dose once weekly. Suboptimal response may include poor growth, deteriorating biochemical markers, or persistent/worsening organomegaly. In the trials, dose titration to 3 mg/kg dose was reported between 4 and 88 weeks after initial treatment dose (median: 11 weeks). The time point in which dosing was escalated to 5 mg/kg in the 2 continuation treatment trials was not described; median duration of exposure to 5 mg/kg was 33 months (range: 27 to 39 months) and 15 months (range: 5 to 24 months) in the 2 treatment groups.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b42c0bec-9b1d-46bf-9943-5f726b01efe1">Lysosomal acid lipase deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lysosomal acid lipase (LAL) deficiency:</b> Infants, Children, and Adolescents: IV: Initial: 1 mg/kg/dose every other week; may increase to 3 mg/kg/dose every other week if response not optimal. Suboptimal response may include poor growth and deteriorating biochemical markers (eg, ALT, AST) and/or parameters of lipid metabolism (eg, LDL-C, triglycerides).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate hypersensitivity reaction: Interrupt infusion; consider resuming at slower infusion rate.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hypersensitivity reaction or anaphylaxis: Immediately discontinue infusion.</p></div>
<div class="block dorp drugH1Div" id="F51159977"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159978"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F45807204"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences are reported for infants, pediatrics, and adults unless specified otherwise.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia (infants)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (infants)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increase in LDL cholesterol (children, adolescents, and adults), increased serum triglycerides (children, adolescents, and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, vomiting (infants)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (infants)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (may be neutralizing)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (children, adolescents, and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (infants), nasopharyngitis, oropharyngeal pain (children, adolescents, and adults), respiratory distress (infants), rhinitis (infants)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children, adolescents, and adults), constipation (children, adolescents, and adults), nausea (children, adolescents, and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (infants: May be delayed as late as 1 year after treatment initiation)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (children, adolescents, and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (children, adolescents, and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, oxygen saturation decreased</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Retching</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, hypotonia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sneezing</p></div>
<div class="block coi drugH1Div" id="F45759570"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed within the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to sebelipase alfa or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F46127905"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Hypersensitivity reactions have occurred during infusion and within 4 hours after the infusion. Anaphylaxis has occurred as early as the sixth infusion and as late as 1 year after treatment initiation. During infusion, appropriate medical treatment should be immediately available. Depending on severity of hypersensitivity reaction, management may include temporary interruption, lowering infusion rate, and/or administration of antihistamines, antipyretics, and/or corticosteroids. If interrupted, the infusion may be resumed at a slower rate with increases as tolerated. Pretreatment with antipyretics and/or antihistamines may prevent subsequent reactions in those cases where symptomatic treatment was required. If anaphylaxis or severe hypersensitivity occurs, immediately discontinue infusion and initiate appropriate medical treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Patients have developed anti-drug antibodies (ADA) to sebelipase alfa and may be more likely to experience hypersensitivity reactions. Some patients with neutralizing antibodies experienced decreased growth velocity. No clear association exists between the development of ADA and decreased efficacy in patients.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergy to egg or egg products: Sebelipase alfa is produced in egg whites of genetically engineered chickens; consider the risks and benefits in patients with known systemic hypersensitivity reactions to eggs or egg products.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878813"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">From clinical trials, the reported incidence of hypersensitivity reactions was 20% for all patients (21 of 106 patients); however, the incidence in the infant age group was 64% (nine of 14 patients); patients were not premedicated prior to sebelipase alfa infusions during the trials. Hypersensitivity reaction presentation in two or more patients included the following signs and symptoms: Abdominal pain, agitation, fever, chills, diarrhea, eczema, edema, hypertension, irritability, laryngeal edema, nausea, pallor, pruritus, rash, and vomiting.   </p></div>
<div class="block foc drugH1Div" id="F45820939"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kanuma: 20 mg/10 mL (10 mL) [contains albumin human, egg white (egg protein)]</p></div>
<div class="block geq drugH1Div" id="F45820937"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46105224"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Kanuma Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/10 mL (per mL): $1,225.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872119"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kanuma: 20 mg/10 mL (10 mL) [contains albumin human, egg white (egg protein)]</p></div>
<div class="block adm drugH1Div" id="F46127939"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer diluted solution as an IV infusion using low-protein-binding infusion set with in-line, low-protein-binding 0.2 micron filter. Infuse over at least 2 hours; may consider 1-hour infusion for those patients receiving 1 mg/kg dose who tolerate a 2-hour infusion. Consider further prolonging infusion time for doses &gt;1 mg/kg or if hypersensitivity reaction occurs.</p></div>
<div class="block admp drugH1Div" id="F52614637"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV infusion: Administer diluted solution (0.1 to 1.5 mg/mL) using low-protein-binding infusion set with in-line, low-protein-binding 0.2 micron filter. Infuse IV over at least 2 hours; may consider 1-hour infusion for those patients receiving 1 mg/kg dose who tolerate a 2-hour infusion. Consider further prolonging infusion time for doses &gt;1 mg/kg/dose or if hypersensitivity reaction occurs.</p></div>
<div class="block use drugH1Div" id="F45759569"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Lysosomal acid lipase deficiency:</b> Treatment of patients with lysosomal acid lipase (LAL) deficiency</p></div>
<div class="block cyt drugH1Div" id="F45785892"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45785889"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F46127903"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies. Sebelipase alfa is a recombinant form of lysosomal acid lipase (LAL), an essential enzyme required for lipid metabolism (Burton 2015; Shirley 2015).</p></div>
<div class="block brc drugH1Div" id="F46127904"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sebelipase alfa is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F46127941"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of hypersensitivity reaction (during infusion and for at least 4 hours after completion of infusion); lipid panel; anti-drug antibody assessment; hepatic function (ALT).</p></div>
<div class="block pha drugH1Div" id="F46127910"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sebelipase alfa binds to cell surface receptors via glycans expressed on the protein and is subsequently internalized into lysosomes. Sebelipase alfa catalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides to free cholesterol, glycerol, and free fatty acids. In patients with lysosomal acid lipase (LAL) deficiency, replacement with sebelipase alfa, a recombinant form of LAL, results in improvement in disease-related hepatic and lipid parameters. </p></div>
<div class="block phk drugH1Div" id="F46127912"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset:</p>
<p style="text-indent:-2em;margin-left:4em;">LDL-c and triglycerides reduction: Within 8 weeks; a transient increase in these values occurs during first 2 to 4 weeks of treatment</p>
<p style="text-indent:-2em;margin-left:4em;">ALT reduction: Within 2 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Effects on ALT partially reverse 3 weeks after treatment discontinuation (Balwani 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:6em;">4 to 11 years: 3.6 ± 3 L</p>
<p style="text-indent:-2em;margin-left:6em;">12 to 17 years: 5.4 ± 2.4 L</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 5.3 ± 1.6 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children ≥4 years, Adolescents, and Adults: Mean range: 5.4 to 6.6 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Children ≥4 years, Adolescents, and Adults: Mean range: 1.1 to 1.3 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45784084"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kanuma</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23348766">
<a name="23348766"></a>Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. <i>Hepatology</i>. 2013;58(3):950-957. doi:10.1002/hep.26289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sebelipase-alfa-drug-information/abstract-text/23348766/pubmed" id="23348766" target="_blank">23348766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26352813">
<a name="26352813"></a>Burton BK, Balwani M, Feillet F, et al. A Phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. <i>N Engl J Med</i>. 2015;373(11):1010-1020. doi:10.1056/NEJMoa1501365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sebelipase-alfa-drug-information/abstract-text/26352813/pubmed" id="26352813" target="_blank">26352813</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kanuma (sebelipase alfa) [prescribing information]. Boston, MA: Alexion Pharmaceuticals; November 2021.</div>
</li>
<li>
<div class="reference">
                  Kanuma (sebelipase alfa) [product monograph]. Zurich, Switzerland: Alexion Pharma GmbH; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26452566">
<a name="26452566"></a>Shirley M. Sebelipase alfa: first global approval. <i>Drugs</i>. 2015;75(16):1935-1940. doi: 10.1007/s40265-015-0479-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sebelipase-alfa-drug-information/abstract-text/26452566/pubmed" id="26452566" target="_blank">26452566</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 105704 Version 78.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
